Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors constitute a novel treatment option, as first- or second-line therapy for pre- or postmenopausal women with hormone receptor-positive (HR+)/HER2-negative (HER2–) metastatic or advanced breast cancer. These targeted agents have the potential to stop or postpone progression at different stages in the disease course, with manageable adverse effects. Two illustrative case studies demonstrate real-world practical applications.
Case studies with interactive benchmarking
To educate oncology nurse practitioners and physician assistants on the role of CDK4/6 inhibitors in managing HR+/HER2− metastatic or advanced breast cancer
After completing this activity, participants should be better able to:
- Summarize evidence supporting the efficacy and safety of CDK4/6 inhibitors for the treatment of HR+/HER2– metastatic or advanced breast cancer
- Identify appropriate candidates for each CDK4/6 inhibitor based on patient and therapy characteristics
- Develop strategies to identify and appropriately manage side effects of CDK4/6 inhibitors so that members of the oncology team can more effectively coordinate patient care and promote adherence
Oncology NPs, PAs, and nurses
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse Planner: Katie Zahasky, NP
PA Planner: Jessica Garner, PA
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until December 17, 2019. PAs should only claim credit commensurate with the extent of their participation.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Lilly USA, LLC.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Schwartzberg: consultant: Amgen, AstraZeneca, Pfizer.
The Planning Committee for this activity included Jessica Garner, PA-C, of the University of the Pacific; Katie Zahasky, NP, of Rochester, MN; and Ruth Cohen and Stephanie Stendardo of Continuing Education Alliance. The members of the Planning Committee have no relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the activity in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: December 17, 2018
Expiration date: December 17, 2019
© 2019 Practicing Clinicians Exchange. All Rights Reserved. LPCE94518